PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients
Monaldi Archives for Chest Disease · 2023
DOI: 10.4081/monaldi.2023.2778 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Monaldi Archives for Chest Disease, 2023. Verfasst von Yoldez Houcine und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Salah Azaiz Institute, Tunis; Faculty of Medicine of Tunis, El Manar University, Tunis. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In cancer treatment, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are thriving. Activated T lymphocytes expressed PD-1, it works with its ligand PD-L1 to limit T lymphocyte activation and prevent autoimmune disease. The expression of molecular biomarkers and PD-L1 in lung cancer determines the appropriate treatment strategy for patients with lung cancer. The purpose of this study was to look at the prevalence of molecular biomarkers and PD-L1 expression in a large group of Tunisian patients with advanced non-small cell lung cancer. We conducted an observational retrospective study in which medical/treatment history data were extracted retrospectively from medical records and archived tissue samples between January 1st 2019 and December 31st 2021. We gathered 157 patients who had recently been diagnosed with non-small cell lung carcinoma. In 36.9%of the cases, there was no molecular genotyping. EGFR (28.6%), KRAS (5.73%), and ALK gene rearrangement were the most common genotyping mutations (3.8%). ROS1 rearrangement was not present. There was a link between EGFR and gender, HER and age, and KRAS and biopsy tissue origin. Six of the tested cases with PD-L1 met the cut-off (³50%). PD-L1 positivity was more common in solid type adenocarcinoma (1.9%) than in acinar or papillary adenocarcinoma. There were no significant differences in PD-L1 expression across clinical and demographic parameters. High PD-L1 expression and molecular abnormalities were found in 1 case of EGFR, 1 case of BRAF, and 1 case of KRAS (3 cases). All of the other specimens with abnormalities had a PD-L1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pathology Department, Salah Azaiz Institute, Tunis; Faculty of Medicine of Tunis, El Manar University, Tunis.
- Faculty of Medicine of Tunis, El Manar University, Tunis; Pneumology Department 1, Abderrahmen Mami Hospital, Ariana.
- Epidemiology and Statistics Department, Farhat Hached Hospital, Sousse.
- Faculty of Medicine of Tunis, El Manar University, Tunis; Pathology Department, Abderrahmen Mami Hospital, Ariana.
ORCID-Profile: Yoldez Houcine, Chirine Moussa
Zitieren
APA
Houcine, Y., Moussa, C., Ben Abdelaziz, A., & Ayadi, A. (2023). PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2023.2778
Vancouver
Houcine Y, Moussa C, Ben Abdelaziz A, Ayadi A. PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients. Monaldi Archives for Chest Disease. 2023. doi:10.4081/monaldi.2023.2778
BibTeX
@article{Houcine2023,
author = {Houcine, Yoldez and Moussa, Chirine and Ben Abdelaziz, Ahmed and Ayadi, Aida},
title = {PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients},
journal = {Monaldi Archives for Chest Disease},
year = {2023},
doi = {10.4081/monaldi.2023.2778}
}
EUVIMED